EGFR and non-small cell lung carcinoma: The main mechanisms of resistance identified to date include secondary mutations and an “oncogene kinase switch.” The EGFR T790M mutation accounts for 50% of cases, and MET amplification can be detected in 20% of patients with EGFR-mutant TKI-resistant NSCLC [17].